1. 6-Gingerol Ameliorates Hepatic Steatosis via HNF4α/miR-467b-3p/GPAT1 CascadeSummary
- Author
-
Chang Hwa Jung, Hyunjung Lee, Hyo-Deok Seo, Jiyun Ahn, Young In Kim, Tae-Youl Ha, and Seung Yeon Ha
- Subjects
0301 basic medicine ,Male ,HFD, high-fat diet ,Catechols ,Gene Expression ,ACC, acetyl-CoA carboxylase ,RC799-869 ,Pathogenesis ,Mice ,0302 clinical medicine ,Genes, Reporter ,Non-alcoholic Fatty Liver Disease ,Nonalcoholic fatty liver disease ,miRNA, microRNA ,Original Research ,chemistry.chemical_classification ,Chemistry ,Fatty liver ,Gastroenterology ,MicroRNA ,1-Acylglycerol-3-Phosphate O-Acyltransferase ,Diseases of the digestive system. Gastroenterology ,mRNA, messenger RNA ,ChIP, chromatin immunoprecipitation ,Hepatocyte nuclear factors ,HF, high-fat diet–fed group ,UTR, untranslated region ,Hepatocyte Nuclear Factor 4 ,030211 gastroenterology & hepatology ,RNA Interference ,Fatty Alcohols ,Intracellular ,medicine.medical_specialty ,TAG, triacylglycerol ,DNL, de novo lipogenesis ,HNF4α, hepatocyte nuclear factor 4α ,6-G, 6-gingerol ,GPAT1 ,03 medical and health sciences ,Structure-Activity Relationship ,cDNA, complementary DNA ,GPAT, glycerol-3-phosphate acyltransferase ,Internal medicine ,NAFLD ,microRNA ,FFA, free fatty acid ,medicine ,Animals ,Humans ,HNF4α ,Hepatology ,DARTS, drug-affinity–responsive target stability ,TLDA, TaqMan low-density arrays ,Fatty acid ,medicine.disease ,Lipid Metabolism ,Disease Models, Animal ,MicroRNAs ,030104 developmental biology ,Endocrinology ,Gene Expression Regulation ,LysoPA, lysophosphatidic acid ,NAFLD, nonalcoholic fatty liver disease ,Steatosis ,6-gingerol - Abstract
Background & Aims The development of nonalcoholic fatty liver disease (NAFLD) can be modulated by microRNAs (miRNA). Dietary polyphenols modulate the expression of miRNA such as miR-467b-3p in the liver. In addition, 6-gingerol (6-G), the functional polyphenol of ginger, has been reported to ameliorate hepatic steatosis; however, the exact mechanism involved and the role of miRNA remain elusive. In this study, we assessed the role of miR-467b-3p in the pathogenesis of hepatic steatosis and the regulation of miR-467b-3p by 6-G through the hepatocyte nuclear factor 4α (HNF4α). Methods miR-467b-3p expression was measured in free fatty acid (FFA)-treated hepatocytes or liver from high-fat diet (HFD)-fed mice. Gain- or loss-of-function of miR-467b-3p was induced using miR-467b-3p–specific miRNA mimic or miRNA inhibitor, respectively. 6-G was exposed to FFA-treated cells and HFD-fed mice. The HNF4α/miR-467b-3p/GPAT1 axis was measured in mouse and human fatty liver tissues. Results We found that miR-467b-3p was down-regulated in liver tissues from HFD-fed mice and in FFA-treated Hepa1-6 cells. Overexpression of miR-467b-3p decreased intracellular lipid accumulation in FFA-treated hepatocytes and mitigated hepatic steatosis in HFD-fed mice via negative regulation of glycerol-3-phosphate acyltransferase-1 (GPAT1). In addition, miR-467b-3p up-regulation by 6-G was observed. 6-G inhibited FFA-induced lipid accumulation and mitigated hepatic steatosis. Moreover, it increased the transcriptional activity of HNF4α, resulting in the increase of miR-467b-3p and subsequent decrease of GPAT1. HNF4α/miR-467b-3p/GPAT1 signaling also was observed in human samples with hepatic steatosis. Conclusions Our findings establish a novel mechanism by which 6-G improves NAFLD. This suggests that targeting of the HNF4α/miR-467b-3p/GPAT1 cascade may be used as a potential therapeutic strategy to control NAFLD., Graphical abstract
- Published
- 2021